We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBioLineRx Ltd

BioLineRx Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.6 USD 0.11 ( 7.38%)
Last update at 2026-11-12T15:15:00Z
VOLUME
493
Market Cap
20.98M

Momentum Score

…

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.56
Low
1.60
High
52 Week Price Range
0.23
Low
1.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioLineRx Ltd is an Israeli clinical-stage biopharmaceutical company that advances therapeutic candidates in oncology and other therapeutic areas through internal development and collaborations. Long-term growth may be supported by positive clinical trial outcomes, licensing or partnership deals that commercialize assets, and milestone-driven de‑risking of its pipeline. The company may appeal to investors seeking event-driven biotech upside tied to development milestones.

Principal risks include high binary clinical and regulatory outcomes, likely ongoing financing needs given limited commercial revenue, and competitive and execution risk in drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.49
Dividend Yield
-
Revenue TTM
17.05M
Revenue Per Share
0.24
Gross Profit TTM
0.00M
Debt / Equity
0.88
ROE
-171.94%
Net Debt
7.34M
ROCE
-88.16%
Diluted EPS TTM
-0.30

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.95M -27.05M -30.02M -25.45M -22.96M
Net income -18.87M -28.14M -30.93M -26.81M -18.51M
Selling general administrative 5.07M 4.27M 3.84M 3.74M 4.41M
Selling and marketing expenses 6.46M 1.00M 0.84M 0.86M 1.36M
Gross profit - - - - 0.00M
Reconciled depreciation 0.65M 0.70M 0.93M 0.94M 0.55M
Ebit -29.16M -24.78M -22.93M -28.11M -25.61M
Ebitda -22.14M -23.43M -22.34M -26.89M -26.85M
Depreciation and amortization 7.02M 1.35M 0.59M 1.22M -1.25M
Operating income -29.16M -24.78M -22.93M -28.11M -25.61M
Other operating expenses 29.16M 24.78M 22.93M 28.11M 25.61M
Interest expense 2.16M 0.98M 1.47M 1.83M 0.02M
Interest income 0.69M 0.56M 0.24M 0.78M 0.72M
Net interest income -1.12M -0.45M -1.26M -1.08M 0.70M
Income tax expense -6.08M 1.09M 0.91M 1.36M -4.46M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 29.16M 24.78M 22.93M 28.11M 25.61M
Cost of revenue - - - - 0.00M
Total other income expense net 4.21M -2.28M -7.09M 2.67M 2.64M
Net income from continuing ops -24.95M -27.05M -30.02M -25.45M -22.96M
Net income applicable to common shares - -27.05M -30.02M -25.45M -22.96M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 63.92M 76.38M 81.39M 47.29M 53.57M
Intangible assets 14.85M 21.89M 21.70M 21.71M 21.89M
Other current assets 1.53M 41.41M 0.13M 0.15M 0.11M
Total liab 50.70M 25.54M 13.30M 25.26M 20.19M
Total stockholder equity 13.22M 50.84M 68.09M 22.03M 33.38M
Other current liab 3.35M 1.74M 1.23M 1.44M 0.01M
Common stock 31.36M 27.10M 21.07M 9.87M 4.69M
Capital stock 31.36M 27.10M 21.07M 9.87M 4.69M
Retained earnings -390.61M -329.99M -305.04M -277.99M -247.97M
Other liab - - 1.86M 10.22M 0.66M
Other assets 0.00M - - - -
Cash 4.25M 10.59M 12.99M 16.83M 5.30M
Total current liabilities 30.85M 10.68M 9.72M 10.64M 11.97M
Current deferred revenue 12.96M - - 0.00M 1.27M
Net debt 7.34M 1.74M -8.34M -9.15M 5.16M
Short term debt 3.67M 1.97M 2.92M 3.28M 2.89M
Short long term debt 3.15M 1.54M 2.76M 3.09M 2.69M
Short long term debt total 11.59M 12.32M 4.65M 7.68M 10.46M
Other stockholder equity 355.48M 340.38M 340.32M 279.24M 265.94M
Property plant equipment - - 2.28M 2.70M 3.47M
Total current assets 47.18M 52.00M 57.40M 22.88M 28.21M
Net tangible assets - - 46.38M 0.32M 11.49M
Short term investments 38.74M 40.49M 44.15M 5.76M 22.19M
Net receivables 0.71M 0.72M 0.14M 0.14M 0.61M
Long term debt 6.63M 8.63M - 2.74M 5.80M
Inventory 1.95M -41.22M - - -
Accounts payable 10.87M 6.97M 5.57M 5.92M 7.79M
Accumulated other comprehensive income 16.99M 13.35M 11.74M 10.91M 10.72M
Common stock total equity - - - 9.87M 4.69M
Non currrent assets other -0.00M - - 21.40M 25.36M
Non current assets total 16.74M 24.38M 23.99M 24.41M 25.36M
Capital lease obligations 1.82M 2.16M 1.89M 1.85M 1.96M
Long term debt total - - - - 7.56M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 4.01M -38.13M 16.67M 5.26M 9.55M
Change to liabilities 0.00M -0.56M -1.72M 3.22M -0.77M
Total cashflows from investing activities - -38.22M 16.67M 5.26M 9.55M
Net borrowings - -3.57M -3.36M -1.10M 9.22M
Total cash from financing activities 20.44M 57.75M 17.87M 19.19M 13.10M
Change to operating activities - 0.02M 0.43M 1.11M -0.93M
Net income -24.95M -27.05M -30.02M -25.45M -22.96M
Change in cash -2.40M -3.84M 11.53M 1.89M -1.71M
Begin period cash flow 12.99M 16.83M 5.30M 3.40M 5.11M
End period cash flow 10.59M 12.99M 16.83M 5.30M 3.40M
Total cash from operating activities -26.24M -23.57M -23.21M -22.67M -24.19M
Issuance of capital stock 14.36M 50.41M 21.21M 20.30M 3.83M
Depreciation 0.65M 0.70M 0.93M 0.94M 0.55M
Other cashflows from investing activities - - - 5.33M 19.77M
Sale purchase of stock - - - 20.30M 3.88M
Other cashflows from financing activities 9.13M 10.91M 0.01M 0.00M 9.68M
Change to netincome - 3.32M 6.58M -2.96M -0.07M
Capital expenditures 0.32M 0.10M 0.10M 0.07M 10.22M
Change in working capital 1.24M -0.54M -1.29M 4.32M -1.71M
Stock based compensation 2.25M 1.50M 1.27M 1.76M 2.53M
Other non cash items -5.43M 0.04M 0.24M -0.07M -2.59M
Free cash flow -26.56M -23.67M -23.21M -22.74M -34.41M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BLRX
BioLineRx Ltd		 0.11
7.38%		 1.60 - - 1.23 2.47 1.25 -0.67
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

BioLineRx Ltd

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

972 8 642 9100

https://www.biolinerx.com

79

Name Title Year Born
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA Chief Exec. Officer 1960
Ms. Mali Zeevi CPA, CPA Chief Financial Officer 1976
Dr. Ella Sorani Chief Devel. Officer 1968
Mr. John Lacey Head of Corp. Communications & Investor Relations NA
Advocate Norman Kotler Internal Enforcement Officer, Gen. Counsel and Corp. Sec. 1952
Ms. Liron Shemesh-Darvish M.B.A., Ph.D. Sr. Director & Head of Preclinical Devel. NA
Ms. Jael Birenberg M.Sc. Sr. Director & Head of RA, QA and PhV NA
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. Head of BD & Strategic Advisor NA
Ms. Holly W. May M.B.A. Pres of BioLineRx USA NA
Mr. Raziel Fried Treasurer & Budgetary Control Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…